Calcbench

The headline number The four largest cloud providers now report nearly $2.4 trillion of remaining performance obligations (RPO): revenue under signed contracts that has not yet been recognized. The totals are easy to add up. They are much harder to compare, because each company describes the timing of that backlog in a different way. Before we get into the analysis, at the bottom are the tags and the datapoints that we used to get the data directly out of Calcbench. Company RPO ($B) As of Scope Microsoft 684.0 Jun 30, 2026 Company-wide ($678B commercial) Oracle 664.0 Aug 31, 2026 Company-wide...

Revenue Performance Obligations (RPO) represent the value of contracted revenue that a company has committed to deliver in future periods under existing customer agreements. RPO includes both short-term and long-term contractual commitments and reflects the remaining value of signed arrangements that have not yet been recognized as revenue. It provides a measure of future revenue that is already contractually secured. Across the S&P 500 companies included in this review, 151 firms reported RPO in both Q3 2025 and Q3 2024, and the median year-over-year change among those firms was an increase of 11.6%. One challenge with RPO disclosures is that companies place this information in widely varied locations within their filings — making it difficult for investors or analysts to retrieve consistently without a structured database. For example:  - Boeing includes RPO inside a paragraph titled “Backlog” within its segment and revenue disclosure.  - Microsoft reports it in ...

Here's a short summary of drug sales for 4 pharmaceutical companies from earnings reports in Q2 '24. Two of the firms reported this morning (July 30th) so the data is fresh.   Included in this small sample are Johnson & Johnson (ticker: JNJ), Pfizer (ticker: PFE), Abbvie (ticker: ABBV) and Merck (ticker: MRK). Using our Excel Add in and our Disclosures query tools, we are able to extract these segments in a flash.   A few noteworthy things.  Drugs that formed a significant portion of revenue in Q2 2024 are  Merck Keytruda (45%) and Gardasil (15%)   J&J  Stelara (13%) and Darzalex (13%)  AbbVie Humira (16%) Skyrizi (16%) Pfizer Elliquis (14%) Time Series of Revenues by Firm / Drug below